Clinical pharmacokinetics of oxaliplatin: A critical review

Clinical Cancer Research

Volumn 6, Issue 4, 2000, Pages 1205-1218

  Graham, Martin A ^a,d   Lockwood, Graham F ^a   Greenslade, Dennis ^a   Brienza, Silvano ^b   Bayssas, Martine ^b   Gamelin, Erick ^c  

^a Sanofi Research Division   (United States)

^b DEBIOPHARM SA   (Switzerland)

^c CENTRE PAUL PAPIN   (France)

^d Sanofi Synthelabo ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COORDINATION COMPOUND; FLUOROPYRIMIDINE; OXALIPLATIN; PLATINUM COMPLEX;

BIOTRANSFORMATION; BLOOD SAMPLING; CANCER PATIENT; COLORECTAL CANCER; COMPLEX FORMATION; COVALENT BOND; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; GLOMERULUS FILTRATION RATE; HUMAN; PRIORITY JOURNAL; REVIEW; STEADY STATE; ULTRAFILTRATION;

ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOTRANSFORMATION; HUMANS; METABOLIC CLEARANCE RATE; ORGANOPLATINUM COMPOUNDS;

EID: 0034006524     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Mamenta, E. L., Poma, E. E., Kaufmann, W. K., Delmastro, D. A., Grady, H. L., and Chaney, S. G., Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res., 54: 3500-3505, 1994.
2. Rixe, O., Ortuzar, W., Alvarez, A., Parker, R., Reed, E., Paull, K., and Fojo, T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen Panel. Biochem. Pharmacol., 52: 1855-1865, 1996.
3. Schmidt, W., and Chaney, S. G. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res., 53: 799-805, 1993.
4. Rietbroek, R. C., van de Vaart, P. J. M., Haveman, J., Blommaert, F. A., Geerdink, A., Bakker, P. J. M., and Veenhof, C. H. N. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J. Cancer Res. Clin. Oncol., 123: 6-12, 1997.
5. Kidani, Y., Inagaki, K., and Saito, R. Synthesis and anti-tumor activities of platinum (II) complexes of 1,2-diaminocyclohexane isomers and their related derivatives. J. Clin. Hematol. Oncol., 7: 197-209, 1977.
6. Kraker, A. J., and Moore, C. W. Accumulation of cis-diamminedichloroplatinum (II) and platinum analogues by platinum-resistant murine leukemia cell in vitro. Cancer Res., 48: 9-13, 1998.
7. Pendyala, L., and Creaven, P. J. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res., 53: 5970-5976, 1993.
8. Silvestro, L., Anal, H., Sommer, F., Trincal, G., and Tapiero, H. Comparative effects of a new platinum analog (trans-1-diaminecyclohexane oxalato-platinum; L-OHP) with CDDP on various cells: correlation with intracellular accumulation. Anticancer Res., 10: 1376, 1990.
9. Fukuda, M., Ohe, Y., Kanzawa, F., Oka, M., Hara, K., and Saijo, N. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sub-lines resistant to cisplatin. Anticancer Res., 15: 393-398, 1995.
10. Riccardi, A., Meco, D., Lasorella, A., Mastrangelo, R., Rumi, C., and Riccardi, R. Comparison of cytotoxicity of oxaliplatin, cisplatin, and carboplatin in human neuroblastoma (NB) cell lines. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 16: 249, 1997.
11. Dunn, T. A., Schmoll, H. J., Grünwald, V., Bokemeyer, C., and Casper, J. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest. New Drugs. 15: 109-114, 1997.
12. Bleiberg, H., and de Gramont, A. Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. Semin. Oncol., 25: 32-39, 1998.
13. de Gramont, A., Figer, A., Seymour, M., Homerin, M., Le Bail, N. Cassidy, J., Boni, C., Cortes-Funes, H., Freyer, G., Hendler, D., and Louvet, C. A randomized trial of leucovorin (LV) and 5-fluorouracil (5-FU) with or without oxaliplatin in advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 17: 257, 1998.
14. Levi, F., Misset, J-L., Brienza, S., Adam, R., Metzger, G., Itzakhi, M., Caussanel, J., Kunstlinger, F., Lecouturier, S., Descorps-Declère, A., Jasmin, C., Bismuth, H., and Reinberg, A. A chronopharmacologic Phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using ambulatory multichannel programmable pump: high antitumor effectiveness against metastatic colorectal cancer. Cancer (Phila.). 69: 893-900, 1992.
15. Levi, F., Dogliotti, L., Perpoint, P., Zidani, R., Giacchetti, S., Chollet, P., Le Rol, A., Llory, J. F., Focan, C., Kunstinger, F., Adam, R., Vannetzel, J. M., Letourneau, Y., Jasmin, C., Bismuth, H., and Misset, J. L. A multicenter Phase II trial of intensified chronotherapy with oxaliplatin (L-OHP), 5-fluorouracil (5FU), and folinic acid (FA) in patients (pts) with previously untreated metastatic colorectal cancer (MCC). Proc. Am. Soc. Clin. Oncol. Annu. Meet., 16: 266, 1997.
16. Levi, F. A., Zidani, R., Vannetzel, J-M., Perpoint, B., Focan, C., Faggiuolo, R., Chollet, P., Garufi, C., Itzhaki, M., Dogliotti, L., Iacobelli, S., Adam, R., Kunstlinger, F., Gastiaburu, J., Bismuth, H., Jasmin, C., and Misset, J. L. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J. Natl. Cancer Inst., 86: 1608-1617, 1994.
17. Levi, F., Zidani, R., and Misset, J-L. Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet, 350: 681-686, 1997.
18. Giacchetti, S., Zidani, R., Perpoint, P., Pinel, M. C., Faggiuolo, R., Focan, C., Letourneau, Y., Chollet, P., Llory, J. F., Coudet, B., Bertheault-Cvitkovic, F., Adam, R., Le Bail, N., Misset, J. L., Bayssas, M., and Levi, F. Phase III trial of 5-flurouracil (5-FU), folinic acid (FA), with or without oxaliplatin (OXA) in previously untreated patients (pts) with metastatic colorectal cancer (MCC). Proc. Am. Soc. Clin. Oncol. Annu. Meet., 16: 229, 1997.
19. 2 by 2 h infusion every three weeks to cancer patients. Sanofi Research Report No. VAR3149, 1998.
20. Graham, M. A., Gamelin, E., Misset, J-L., Brienza, S., Allain, P., Boisdron-Celle., Krikorian, A., Greenslade, D., and Bayssas, M. Clinical pharmacokinetics of oxaliplatin. Proc. Am. Assoc. Cancer Res., 39: 159, 1998.
21. Allen, J., Graham, M. A., Firth, J., Woolfrey, S., Greenslade, D., Morrison, J. G., McDougall, S., Ross, P., and Cunningham, D. Biotransformation and pharmacokinetic analysis of oxaliplatin in patients with advanced gastrointestinal cancer. Proc. Am. Assoc. Cancer Res., 39: 159, 1998.
22. Allen, J., Graham, M. A., Watson, D., Chung, D., Tabah-Fisch, I., Ross, P., and Cunningham, D. A clinical metabolism and pharmacokinetic study of oxaliplatin plus 5-fluorouracil in patients with advanced gastrointestinal cancer. Sanofi Research Report No. PKM2983 (part 1), 1998.
23. Kern, W., Braess, J., Bottger, B., Kaufmann, C. C., Hiddemann, W., and Schleyer, E. Oxaliplatin pharmacokinetics during a four-hour infusion. Clin. Cancer Res., 5: 761-765, 1999.
24. Graham, M. A. A clinical metabolism and pharmacokinetic study of oxaliplatin plus 5-fluorouracil in patients with advanced gastrointestinal cancer. Sanofi Research Report No. PKM2983 (part 2), 1998.
25. Woolfrey, S., Le Bouil, A., and Allain, P. Validation of platinum determination in biological fluids by inductively coupled plasma mass spectrometry. Sanofi Research Report No. DOH0127, 1998.
26. Morrison, J. D. Validation of an inductively coupled plasma-mass spectrometry (ICPMS) assay for the determination of platinum in human blood, plasma, and ultrafiltrate. Sanofi Research Report No. DOH0088, 1998.
27. Taguchi, T. The final report of the Phase I clinical study of ACT-078 (oxaliplatin). Debiopharm/Sanofi Research Report No. TDU3131, 1998.
28. Marty, M. L-OHP Phase I study. Debiopharm/Sanofi Report No. TDU3099, 1989.
29. Gamelin. E., Le Bouil, A., Boisdron-Celle, M., Turcant, A., Delva, R., Cailleux, A., Krikorian, A., Brienza, S., Cvitkovic, E., Robert, J., Larra, F., and Allain, P. Cumulative pharmacokinetic study of oxaliplatin administered every three weeks combined with 5-fluorouracil in colorectal cancer patients. Clin. Cancer Res., 3: 891-899, 1997.
30. Misset, J. L., and Allain, P. Pharmacokinetics, urinary, and fecal excretion of oxaliplatin in cancer patients. Debiopharm/Sanofi Report No. TDR3500, 1995.
31. 3H]-oxaliplatin in human microsomes. Sanofi Research Report No. MIV0249, 1997.
32. Brandl, J., and Brian, W. Investigating the potential for SR96669 to inhibit cytochrome P450 (CYP) enzymes using human liver microsomes in vitro. Sanofi Research Report No. MIH0034, 1998.
33. 3H]-oxaliplatin in human microsomes. Sanofi Research Report No. MIV0250, 1997.
34. 3H]-oxaliplatin in human plasma ultrafiltrate and urine. Sanofi Research Report No SPP0111, 1998.
35. Massari, C., Brienza, S., Rotarski, M., Gastiaburu, J., Misset, J. L., Cupissol, D., Alafaci, E., Dutertre-Catella, H., and Bastian, G. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother. Pharmacol., 45: 157-164, 2000.
36. Graham, M. A., Lockwood, G. F., Cunningham, D., and Gamelin, E. Pharmacokinetics of oxaliplatin in special patient populations. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 18: 189, 1999.
37. Papamichael, D., Joel, S. P., Seymour, M. T., Richards, F., Bowerbank, M., and Slevin, M. L. Pharmacokinetic (PK) interaction between 5-fluorouracil (5-FU), and oxaliplatin (L-OHP). Proc. Am. Soc. Clin. Oncol. Annu. Meet., 17: 202, 1998.
38. Papamichael, D., Joel, S. P., Seymour, M. T., Richards, F., Bowerbank, M., Slevin, M. L., and Graham, M. A. Pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. Sanofi Research Report No. INT3681, 1998.
39. Calvert, H., Judson, I., and Van der Vijgh, W. J. F. Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity. In: P. Workman, and M. A. Graham (eds.), Cancer Surveys, Vol. 17: Pharmacokinetics and Cancer Chemotherapy, pp. 189-217. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1993.
40. 2 every 3 weeks. Debiopharm/ Sanofi Report No. BDR3103, 1995.
41. Lokiec, F., Wasserman, E., Cvitkovic, E., Santoni, J., Weill, S., Gauzan, M. F., and Misset, J. L. Final results of the pharmacokinetic study of both CPT-11 (C) and LOHP (L) in combination during a Phase I trial in gastrointestinal cancer patients. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 17: 202, 1998.
42. Luo, F. R., Wyrick, S. D., and Chaney, S. G. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cell lines. Oncol. Res., 10: 595-603, 1998.
43. Schrijvers, D., Highley, M., DeBruyn, E., Van Oosterom, A. T., and Vermorken, J. B. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Anticancer Drugs, 10: 147-153, 1999.
44. Uriens, S., and Tillement, J. P. In vitro binding of oxaliplatin to human serum proteins. Drug interactions. Debiopharm Study Report No. LPH0022, 1995.
45. Misset, J. L., Gamelin, E., and Allain, P. Oxaliplatin-induced platinum DNA adducts in white blood cells of cancer patients. Debiopharm/ Sanofi Report No. MIH0035, 1995.
46. Petros, W. P., Chaney, S. G., Smith, D. C., Fangmeier, J., Sakata, M., Brown, T. D., and Trump, D. L. Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with Phase I clinical trial. Cancer Chemother. Pharmacol., 33: 347-354, 1994.
47. Schilder, R. J., La Creta, F. P., Perez, R. P., Johnson, S. W., Brennan, J. M., Rogatko, A., Nash, S., McAker, C., Hamilton, T. C., Roby, D., Young, R. C., Ozols, R. F., and O'Dwyer, P. J. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administrated on a day 1 and day 8 schedule. Cancer Res., 54: 709-717, 1994.
48. Vermorken, J. B., Van der Vijgh, W. J., Klein, I., Hart, A. A., Gall, H. E., and Pinedo, H. M. Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. Cancer Treat. Rep., 68: 503-513, 1984.
49. Elferink, F., Van der Vijgh, W. J. F., Klein, I., Vermorken, J. B., Gall, H. E., and Pinedo, H. M. Pharmacokinetics of diammine (1,1-cyclobutane dicarboxylato) platinum (II) (carboplatin) after intravenous administration. Cancer Treat. Rep., 71: 1231-1237, 1987.